Skip to main content
. Author manuscript; available in PMC: 2019 Sep 27.
Published in final edited form as: Mol Pharm. 2018 May 16;15(6):2069–2083. doi: 10.1021/acs.molpharmaceut.8b00319

Table 6:

MMPs used to improve drug delivery

Particle Duration Source Tumor Type Effect Change in ECM Ref
HS Vector MGH2 7 days MMP-1 and MMP-8 expressing HSTS26T HSTS26T Sarcoma 5–10X increase in viral immunostaining at tumor center
1.3X decrease in tumor growth		 No detectable change in imaged tumor SHG intensity 101
Adwt300 virus Up to 50 days MMP-8 expressing A549 and BxPC-3 cells A549 alveolar adenocarcinoma
BxPC-3 pancreatic cancer		 Increase in viral distribution by viral immunostaining (unquantified)
3X decrease in tumor volume (day 30–50)
Complete survival of animals (BxPC-3)		 3X decrease in visible collagen by histology 102
HSV-eGFP 21 days MMP-9 expressing SK-N-AS SK-N-AS Neuroblastoma 3X increase in GFP positive cells (Spheroids)
Increase tumor vector distribution by viral immunostaining (unquantified)		 N/A 112